Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
09 2020
Historique:
received: 26 08 2019
revised: 27 11 2019
accepted: 30 11 2019
pubmed: 29 12 2019
medline: 7 8 2021
entrez: 29 12 2019
Statut: ppublish

Résumé

The Nutritional Risk Screening 2002 (NRS 2002) identifies patients at risk of malnutrition. We studied the prognostic implications of this score with regard to short-term and long-term clinical outcomes in a well-characterised cohort of medical inpatients from a previous trial. This is a secondary analysis of an investigator-initiated, prospective randomised controlled multicenter trial in Switzerland (EFFORT) that compared the effects of an individualised nutritional support intervention with standard of care. We investigated associations between admission NRS and several short-term and long-term outcomes using multivariable regression analyses. Of the 2028 patients, 31% had an NRS of 3, 38% of 4 and 31% of ≥5 points, and 477 (24%) died during the 180 days of follow-up. For each point increase in NRS, we found a stepwise increase in risk of 30-day mortality (adjusted Hazard Ratio (HR) 1.22 (95% CI 1.00 to 1.48), p = 0.048) and 180-day mortality (adjusted HR 1.37 (95% CI 1.22 to 1.55), p < 0.001). NRS was associated with length of hospital stay (adjusted difference of 0.60 days per NRS point increase, 95%CI 0.23 to 0.97, p = 0.002) and functional outcomes at 180 days (adjusted decrease in Barthel index of -4.49 points per NRS point increase, 95%CI -6.54 to -2.45, p < 0.001). In a subgroup analysis, associations of NRS and short-term adverse outcomes were less pronounced in patients receiving nutritional support (intervention group) compared to control group patients (adjusted HR for 30-day mortality 1.12 [95%CI 0.83 to 1.52, p = 0.454] vs. 1.33 [95%CI 1.02 to 1.72, p = 0.032]). The NRS is a strong and independent risk score for malnutrition-associated mortality and adverse outcomes over 180 days. Our data provide strong evidence that the nutritional risk, however, is modifiable and can be reduced by the provision of adequate nutritional support.

Identifiants

pubmed: 31882232
pii: S0261-5614(19)33171-1
doi: 10.1016/j.clnu.2019.11.041
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2720-2729

Informations de copyright

Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Auteurs

Lara Hersberger (L)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.

Laura Bargetzi (L)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.

Annika Bargetzi (A)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.

Pascal Tribolet (P)

Internal Medicine, Spital Lachen, Switzerland.

Rebecca Fehr (R)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Valerie Baechli (V)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Martina Geiser (M)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Manuela Deiss (M)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Filomena Gomes (F)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; The New York Academy of Sciences, New York City, NY, USA.

Alexander Kutz (A)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.

Nina Kägi-Braun (N)

Internal Medicine, Kantonsspital Muensterlingen, Switzerland.

Claus Hoess (C)

Internal Medicine, Kantonsspital Muensterlingen, Switzerland.

Vojtech Pavlicek (V)

Internal Medicine, Kantonsspital Muensterlingen, Switzerland.

Sarah Schmid (S)

Internal Medicine, Kantonsspital Muensterlingen, Switzerland.

Stefan Bilz (S)

Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.

Sarah Sigrist (S)

Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.

Michael Brändle (M)

Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.

Carmen Benz (C)

Internal Medicine & Endocrinology/Diabetes, Kantonsspital St.Gallen, Switzerland.

Christoph Henzen (C)

Internal Medicine, Kantonsspital Luzern, Switzerland.

Melina Nigg (M)

Internal Medicine, Kantonsspital Luzern, Switzerland.

Robert Thomann (R)

Internal Medicine, Buergerspital Solothurn, Switzerland.

Claudia Brand (C)

Internal Medicine, Buergerspital Solothurn, Switzerland.

Jonas Rutishauser (J)

Internal Medicine, Kantonsspital Baselland, Switzerland.

Drahomir Aujesky (D)

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Nicolas Rodondi (N)

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.

Jacques Donzé (J)

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Zeno Stanga (Z)

Division of Diabetology, Endocrinology, Nutritional Medicine & Metabolism, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Beat Mueller (B)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.

Philipp Schuetz (P)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland. Electronic address: schuetzph@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH